Faculty Disclosures:
All individuals in a position to control the content of this education activity including  members of the planning committee, speakers, presenters, authors, and/or content reviewers have disclosed  all relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

The following relevant financial relationships were disclosed:
•    Antoinette J. Wozniak, MD – Consultant: Lilly Oncology, Regeneron, Epizyme, GlaxoSmith Kline, Novocure, Janssen Inc, Incyte, and Beigene. Other: DSMB BeyondSpring, DSMB Odronate, DSMB HUYA.
•    Jason Luke, MD – Other: DSNB AbbVie, DSMB Immutep, Other/Advisory Board: (7 Hills, Fstar, Inzen, Refle Xion, Xilio, Actym, Alphamab Oncology, Arch Oncology, Kanaph, Mavu, Onc.Al, Pyxis, Tempest, Consultant: AbbVie, Alnylam, Avillion, Bayer, Bristol Meyer Squibb, Checkmate, Codiak, Crown, Day One, Eisai, EMD Serono, Flame, Genentech, Gilead, HotSpot, Kadmon, KSQ, Janssen, Ikena, Immunocore, Incyte, Macrogenics, Merck, Mersana, Nektar, Novartis, Pfizer, Regeneron, Ribon, Rubius, Silicon, Synlogic, Synthekine, TRex, Werewolf, Xencor  Research and Support: AbbVie, Agios (IIT), Astellas, AstraZeneca, Bristol-Meyers Squibb (IIT an d Industry), Corvus, Day One, EMD Serono, Fstar, Genmab, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, Next Cure, Numab, Pfizer (IIT and Industry), Replimmune, Rubis, Scholar rock, Synlogic, Takeda, Trishula, Tizona, Xencor  Patents: (both provisional) Serial # 15/612,657, (Cancer Immunotherapy), PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1: Diagnostic, Prognostic and Therapeutic Uses Thereof)
•    Dan Zandberg, MD – Grant/Research Support: (for my role as PI for trails with): Merck, Bristol Myers-Squibb, Aduro, Glaxo Smith-Kline, Lilly, Checkmate Pharmaceuticals, BICARA, Aethlon, Prelude Therapeutics Consultant: Macrogenics, Blueprint Medicine
•    Shannon Puhalla, MD – Grant/Research Support: AbbVie, Pfizer, Lilly, Novartis, Incyte, Covariance-Bayer, AstraZeneca.
Consultant: AbbVie, MedImmune, Celldex, Puma, Pfizer, AstraZeneca, Esai, nanostring.
•    Adam Brufsky, MD, PhD, FACP – Consultant: Roche, Puma, Seattle Genetics, AstraZeneca, Daiichi, Pfizer, Novartis.
•    Yana Najjar, MD – Grant/Research Support: Merck, Bristol Meyer Squibb, Pfizer  Consultant: Novartis, Array BioPharma, Merck
•    Leonard Appleman, MD, PhD – Consultant: AADi  Grant/Research Support: Pfizer, Exelixis, Bristol Meyer Squibb, Astellas Pharma, Novartis, Bayer, Merck, Genentech/Roche, AVEO, Peleton Therapeutics, Calithera Bioscience, Seattle Genetics, Inovia Pharmaceuticals, Eisai, Lilly, Amgen, Surface Oncology, BioNTech, Epizyme.
Other: Pfizer, Exelixis
•    Taofeek Owonikoko, MD – Research/Funding: Novartis, Astellas Pharma, Bayer, StemCentRX, Regeneron, AstraZeneca, G1 Therapeutics, Bristol Myers, United Therapeutics, Amgen, Loxo/Lilly, Fujifilm, Pfizer Aeglea Biotherapeutics, Incyte, Merck, Mersana, Turning Point, Oncorus, Ispen, Eisai, Roche/Genentech Consultant/Advisory Board: Novartis, Lilly, Sandoz, AbbVie, Eisai, G1 Therapeutics, Bristol-Meyer Squibb, MedImmune, BerGenBio, Lilly, Amgen, AstraZeneca, PharmaMar, Boehringer Ingelheim, EMD Serono, XCovery, Bayer, heron Pharmaceutical, ARMO, BioSeience, Merck, Bayer, Jazz, Zentalis, Ipsen IRC/DSMB: Serono, Roche/Genentech, Other: Cambium Oncology

No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.